Business Wire | Apr 21, 2021 10:19AM EDT

BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2021

Apr. 21, 2021

ROCKVILLE, Md.--(BUSINESS WIRE)--Apr. 21, 2021--BIOQUAL, Inc. (OTC-Pink:BIOQ) (www.bioqual.com):

Nine Months Ended Three Months Ended

February 28, February 29, February 28, February 29,

2021 2020 2021 2020

Revenue $ 41,070,486 $ 32,884,055 $ 12,584,303 $ 11,593,217

Income Before $ 5,942,062 $ 4,150,830 $ 1,379,460 $ 1,018,306Income Tax

Net Income $ 4,203,962 $ 2,936,730 $ 975,960 $ 720,406

Basic Earnings per Share

of Common Stock $ 4.70 $ 3.29 $ 1.09 $ .81

Diluted Earnings per Share

of Common Stock $ 4.70 $ 3.29 $ 1.09 $ .81

Weighted Average

Number of Shares Outstanding

For Basic Earnings 893,932 893,416 894,416 893,416Per Share

Weighted Average

Number of Shares Outstanding

For Diluted 893,932 893,843 894,416 893,843Earnings Per Share

For more detail related to the fiscal year 2021 unaudited third quarter results, please visit our web site at www.bioqual.com.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company's ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company's ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company's contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005716/en/

CONTACT: Mark G. Lewis, Ph.D., CEO (240-404-7654)